Slide background

> Our Technology

DCVax® is a platform
technology that uses
activated dendritic cells

Slide background

> Our Products

DCVax® – L
DCVax® – Direct
DCVax® – Prostate

Slide background

Northwest Biotherapeutics, Inc is a clinical stage biotechnology company focused on the development of personalized cancer vaccines designed to treat a broad range of solid tumor cancers.


Recent Presentations

16
MAR
2023

Immunization With Autologous Dendritic Cells is Associated With Extended Survival in Glioblastoma Patients: Glioblastoma Drug Development Summit

Press Releases

20
MAR
2023

Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility

06
JAN
2023

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023

Follow us On: 

© 2017 Northwest Biotherapeutics, Inc.
4800 Montgomery Lane, Suite 800
Bethesda, MD 20814
Phone: 240-497-9024